Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Research

Temporal trends and socioeconomic differences in acute respiratory infection hospitalisations in children: an intercountry comparison of birth cohort studies

Admissions for ARI were higher in Western Australia and displayed greater socioeconomic disparities than England and Scotland, where ARI rates are increasing

Research

Influenza epidemiology in patients admitted to sentinel Australian hospitals in 2018: the Influenza Complications Alert Network (FluCAN)

This report summarises the epidemiology of hospitalisations with laboratory-confirmed influenza during the 2018 influenza season

Research

Time series analysis of RSV and bronchiolitis seasonality in temperate and tropical Western Australia

Bronchiolitis hospitalisations are a reasonable proxy for the timing of RSV detections, but may not fully capture the magnitude of RSV epidemics

Research

Risk factors and comorbidities for invasive pneumococcal disease in Western Australian Aboriginal and non-Aboriginal people

Australian Aboriginal people have among the highest rates of invasive pneumococcal disease (IPD) worldwide. This paper investigates clinical diagnosis, risk...

Research

Association of gestational age and growth measures at birth with infection-related admissions to hospital throughout childhood

Children who were born with reduced gestational age, birthweight, and birth length have persistently increased rates of infection-related admissions to hospital until age 18 years

Research

Establishing a process for conducting cross-jurisdictional record linkage in Australia

We outline the processes involved in conducting a Proof of Concept data linkage project including the implementation of national data integration principles

Research

Acute lower respiratory infections (ALRI) in Indigenous and non-Indigenous children

In Australia and many other developed countries, acute lower respiratory infection (ALRI) is one of the most common reasons for hospitalisation in young...

Research

“It’s all gone quiet…” MUSIC from COVID19

Hannah Huong Christopher Moore Le Blyth OAM BSc (Hons) GradDipClinEpi PhD MA (Dev. Econ), MA (App. Stats), PhD (Econ) MBBS (Hons) DCH FRACP FRCPA PhD

Research

Effectiveness of nirsevimab in preventing RSV-hospitalisation among young children in Western Australia 2024

Respiratory Syncytial Virus (RSV) causes a significant burden of illness for children under 2 years of age. Nirsevimab, a long-acting monoclonal antibody, was registered for RSV prevention in Australia in 2023. In April 2024, Western Australia (WA) launched the country's first state-wide nirsevimab program for all infants and high-risk children entering their second RSV season. 

Research

The STAMP RSV Program

STAMP RSV is a multifaceted program of work with the single focus to prepare the community for the uptake of new and emerging RSV immunisation strategies by providing the evidence to inform public health policy.